Objectives: To explore the applicability of the current prognostic models for nonmetastatic renal cell carcinoma in the Chinese population based on a single center experience.

Methods: Clinical and pathological variables of 653 nonmetastatic renal cell carcinoma patients were retrospectively reviewed. Seven models were used to predict the prognosis, including the Yaycioglu model, the Cindolo model, the University of California Los Angeles Integrated Staging System model, the stage, size, grade, and necrosis model, the Kattan nomogram, the Sorbellini nomogram and the Karakiewicz nomogram. Three different end-points were used for validation, including overall survival, cancer-specific survival, and recurrence-free survival. Survival was estimated using the Kaplan-Meier method. Discriminating ability was assessed using the Harrell's concordance-index.

Results: At the last follow up, 159 patients had died due to various causes, and disease recurrence occurred in 156 patients. The discriminating ability of all models was confirmed in the Chinese population. Nomograms discriminate better than algorithms, regardless of end-points. The Kattan nomogram was the most accurate, with the highest concordance-indexes of 0.752, 0.793 and 0.841 for overall survival, cancer-specific survival, and recurrence-free survival, respectively.

Conclusions: The current prognostic models were developed and validated entirely based on Caucasian populations. This study defines the general applicability of the models for Chinese patients with nonmetastatic renal cell carcinoma treated with nephrectomy. The Kattan model was found to be the most accurate. The Cindolo model performed well in some situations, although only including clinical presentation and size of tumor. Therefore, models should be chosen according to different environments and purposes.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1442-2042.2008.02229.xDOI Listing

Publication Analysis

Top Keywords

nonmetastatic renal
16
renal cell
16
cell carcinoma
16
current prognostic
12
prognostic models
12
chinese population
12
models nonmetastatic
8
single center
8
cindolo model
8
kattan nomogram
8

Similar Publications

Objectives: To assess the prognostic value of the preoperative serum ferritin-to-transferrin ratio (FTR) in renal cell carcinoma (RCC). Methods:We retrospectively reviewed data from 226 patients who underwent surgery for non-metastatic RCC at our institution between January 1, 2012, and June 30, 2021. Time-dependent receiver operating characteristic (timeROC) analysis identified the optimal FTR cut-off, dividing patients into high and low FTR groups.

View Article and Find Full Text PDF

In renal cell carcinoma (RCC) patients with inferior vena cava (IVC) tumor thrombus, neoadjuvant therapy could alleviate the burden of tumor thrombus, enhance the safety and feasibility of surgical resection, and improve patient prognosis. The combination of tislelizumab and axitinib has demonstrated efficacy in the treatment of advanced RCC. Our study aimed to evaluate the efficacy and safety in the neoadjuvant therapy setting of tislelizumab and axitinib in RCC patients with IVC tumor thrombus.

View Article and Find Full Text PDF

Purpose: Aimed to evaluate the prognostic value of Pan-Immune-Inflammation Value (PIV) for overall survival (OS) in the localized RCC. We also tested the feasibility of incorporating the PIV into UCLA Integrated Staging System (UISS).

Materials And Methods: Retrospectively evaluated 197 consecutive ≥pT2a radical nephrectomy patients.

View Article and Find Full Text PDF

Background: Transitional cell carcinoma (TCC) of the renal pelvis is a rare cancer within the urinary system. However, the prognosis is not entirely satisfactory. This study aims to develop a clinical model for predicting cancer-specific survival (CSS) at 1-, 3-, and 5-year for White Americans with renal pelvic TCC.

View Article and Find Full Text PDF

Objective: To compare operative and oncological outcomes, as well as the risk of postoperative complications in patients who underwent transperitoneal robot-assisted partial nephrectomy (RAPN) for renal tumours located either posteriorly or anterolaterally.

Methods: Retrospective, consecutive study including 451 patients who underwent transperitoneal RAPN for non-metastatic, localised renal tumours from May 2016 to April 2023. Operative data included duration of the procedure, warm ischaemia time, and blood loss; oncological data included surgical margins and recurrence; and 90-day postoperative complications were classified according to the Clavien-Dindo classification.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!